Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
about
Modulatory effects of bortezomib on host immune cell functionsUnderstanding of molecular mechanisms in natural killer cell therapyBiology and clinical effects of natural killer cells in allogeneic transplantation.A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Opportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseProteasome inhibitors in the treatment of multiple myelomaEx vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsNK cell-based immunotherapies in Pediatric Oncology.Immunosurveillance and therapy of multiple myeloma are CD226 dependent.Cell death signaling and anticancer therapyHighly activated and expanded natural killer cells for multiple myeloma immunotherapyBortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunitiesInfusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.Enhancing cytokine-induced killer cell therapy of multiple myeloma.Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibHematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.Combination immune therapies to enhance anti-tumor responses by NK cells.Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responsesNovel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myelomaLow-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.The role of natural killer cells in immunity against multiple myeloma.Combining immunotherapy and targeted therapies in cancer treatment.Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.Strategies for enhancing vaccine-induced CTL antitumor immune responses.Novel immune modulators used in hematology: impact on NK cellsEfficacy of bortezomib as first-line treatment for patients with multiple myeloma.Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.Immunotherapeutic approaches to treat multiple myelomaStaging and prognostication of multiple myelomaCancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityPreclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
P2860
Q26795618-4AB12876-DB4A-4782-9A04-3FF4466E2FDBQ28086976-9F2EB5B4-4A72-4061-A7B0-A8D12552EE37Q33893173-E0F81BB6-7111-451F-89C3-6EBE515F2D8DQ34241208-14884831-C620-4A97-AA08-AEE08041BEC5Q34241661-1E58B732-D01F-4894-B849-CAD46FD04F15Q34307792-0D90FC17-3A47-489D-A5BC-7FE596D06CCEQ34611676-D28846BC-A820-4037-96D2-CACC98B04D2CQ35157421-2F821AFF-94FD-41F3-84E2-3A51965BC0ECQ35600975-0E2E30AE-DA8D-4A0F-AB6E-508CE13AAD3EQ35719883-1555F040-5C4F-4AC3-87FF-8704214A3AA5Q35972102-F84DBE35-14FB-4FA8-8CA4-1FB930ABEADAQ36216203-E47E68D7-9F5A-4461-8244-10C154E62329Q36378038-0A84904C-046B-45FB-BD9F-C5106511F349Q36413676-97243371-466E-4A67-AFC6-4B68149C5FA0Q36447553-65567E12-4E7B-4744-AB6B-6085DB2AC2BEQ36700598-F77F7599-8B48-4247-9FFC-284FD4A6D43BQ36892290-816ACBFC-7B5F-498E-837B-131BF73B2D56Q37071112-E5DBD4E6-8C5D-4B75-9DA8-7F8E38C2D85EQ37235006-315AC6C8-15B5-4C60-A733-F14EE935B6EAQ37277554-EC7D043D-B8A6-41BC-8FD4-DB5B1FA97354Q37357340-F6FFEA05-0EA6-4E61-97A6-BCA587C11CB6Q37408550-7EA23523-B173-4D5E-800C-5EF8274EAF5BQ37524719-D5DBB505-F720-4AF4-B34B-76EA7DA7C655Q37557880-4670A430-FB28-4371-B25D-C63AC551400AQ37701514-556A996A-6BD3-4E0C-95DE-B0AC63869368Q37702765-CC822290-78C8-4EB8-8AE4-B2DD36B53DB9Q37779043-CB6C500E-E33D-42B2-BE67-3E27DE9913EEQ37876363-E7294224-0D88-451D-8CEB-89D2BE77F142Q37994234-1DA3E39D-2AA0-4478-BE01-AC7CE9C29D07Q37995939-F08C8CD9-2097-45F9-A774-FED812ECE6B1Q38035301-F58F07B3-C562-41FB-862D-9E9910CF68CEQ38055143-EC57479E-FE06-495D-9FBA-E60AC74C9069Q38073760-044FEFDD-746A-4C37-A409-227E9D2FDBFEQ38089497-7ED62556-FAB2-4992-A606-FCA53F2FDBCEQ38139998-CC70D32F-E831-47F2-9B4C-22C9D167E113Q38171067-325B40CB-BC2F-4556-813C-0968EE3F17B7Q38183871-AAF906EF-E956-4537-A258-F9405FC39C96Q38203261-A544919D-65EA-4114-A703-C8E58D6E80B2Q38526452-E38881D4-7E50-471B-B910-3BA89321A45CQ38661370-6EEC19F5-346C-4EA6-977C-6C7F956E27AE
P2860
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@ast
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@en
type
label
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@ast
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@en
prefLabel
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@ast
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@en
P2093
P2860
P1433
P1476
Bortezomib down-regulates the ...... ell-mediated lysis of myeloma.
@en
P2093
Arend Mulder
Brian Storrie
Guido J Tricot
John D Shaughnessy
Priyangi A Malaviarachchi
Rachel E Kellum
Susann M Szmania
Tarun K Garg
P2860
P304
P356
10.1182/BLOOD-2007-03-078535
P407
P577
2007-10-18T00:00:00Z